Evaluation of adherence to abiraterone therapy in prostate cancer patients based on a population pharmacokinetic model

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F24%3A43927309" target="_blank" >RIV/00064173:_____/24:43927309 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11110/24:10481731 RIV/00216208:11120/24:43927309 RIV/00216208:11310/24:10481731 RIV/27283933:_____/24:N0000025 RIV/00064165:_____/24:10481731

Result on the web

<a href="https://doi.org/10.1111/bcp.16155" target="_blank" >https://doi.org/10.1111/bcp.16155</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/bcp.16155" target="_blank" >10.1111/bcp.16155</a>

Result language

angličtina

Original language name

Evaluation of adherence to abiraterone therapy in prostate cancer patients based on a population pharmacokinetic model

Original language description

AIMS: Abiraterone treatment requires regular drug intake under fasting conditions due to pronounced food effect, which may impact patient adherence. The aim of this prospective study was to evaluate adherence to abiraterone treatment in patients with prostate cancer. To achieve this aim, an abiraterone population pharmacokinetic model was developed and patients&apos; adherence has been estimated by comparison of measured levels of abiraterone with population model-based simulations. METHODS: A total of 1469 abiraterone plasma levels from 83 healthy volunteers collected in a bioequivalence study were analysed using a nonlinear mixed-effects model. Monte Carlo simulation was used to describe the theoretical distribution of abiraterone pharmacokinetic profiles at a dose of 1000 mg once daily. Adherence of 36 prostate cancer patients treated with abiraterone was then evaluated by comparing the real abiraterone concentration measured in each patient during follow-up visit with the theoretical distribution of profiles based on simulations. Patients whose abiraterone levels were &lt;5th or &gt;95th percentile of the distribution of simulated profiles were considered to be non-adherent. RESULTS: Based on this evaluation, 13 patients (36%) have been classified as non-adherent. We observed significant association (P = .0361) between richness of the breakfast and rate of non-adherence. Adherent patients reported significantly better overall condition in self-assessments (P = .0384). A trend towards a higher occurrence of adverse effects in non-adherent patients was observed. CONCLUSIONS: We developed an abiraterone population pharmacokinetic model and proposed an advanced approach to medical adherence evaluation. Due to the need for administration under fasting conditions, abiraterone therapy is associated with a relatively high rate of non-adherence.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

British Journal of Clinical Pharmacology

ISSN

0306-5251

e-ISSN

1365-2125

Volume of the periodical

90

Issue of the periodical within the volume

10

Country of publishing house

GB - UNITED KINGDOM

Number of pages

11

Pages from-to

2652-2662

UT code for WoS article

001260679800001

EID of the result in the Scopus database

2-s2.0-85197444956